AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and…
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of…